certain related assets, and was granted a right of first nego tiation over the co-development or commercialization of GSK’s current and future oncology R&D pipeline, excluding oncol ogy vaccines; create a joint venture with GSK in consumer healthcare, in which Novartis would own its Vaccines Division (excluding the influenza vaccines busi ness) to GSK.